Congress must continue to support the VA’s research into psychedelics for PTSD - Two members of Congress and a veteran call to keep momentum going

MDMA-assisted therapy and psilocybin in medical contexts should be supported through the Veterans Affairs system so PTSD treatments can reach veterans after FDA review. The essay argues that the VA has begun a turnaround by launching MDMA-assisted therapy clinical trials and that Congress should keep funding psychedelic therapy research and clinician preparation. It cites Phase 3 results for MDMA-assisted therapy for PTSD and a Phase 2 study showing effects of psilocybin for treatment-resistant depression. The authors connect policy to implementation: they point to bipartisan congressional actions, including amendments directing VA evaluation and pilot programs for integrating FDA-approved psychedelic therapies, plus plans for training, supervision, and possible VA Centers of Excellence. They frame access for veterans as urgent to avoid forcing patients to seek treatment abroad.